Applications of single-cell RNA sequencing in drug discovery and development

Bram Van de Sande,Joon Sang Lee,Euphemia Mutasa-Gottgens,Bart Naughton,Wendi Bacon,Jonathan Manning,Yong Wang,Jack Pollard,Melissa Mendez,Jon Hill,Namit Kumar,Xiaohong Cao,Xiao Chen,Mugdha Khaladkar,Ji Wen,Andrew Leach,Edgardo Ferran
DOI: https://doi.org/10.1038/s41573-023-00688-4
IF: 112.288
2023-04-29
Nature Reviews Drug Discovery
Abstract:Single-cell technologies, particularly single-cell RNA sequencing (scRNA-seq) methods, together with associated computational tools and the growing availability of public data resources, are transforming drug discovery and development. New opportunities are emerging in target identification owing to improved disease understanding through cell subtyping, and highly multiplexed functional genomics screens incorporating scRNA-seq are enhancing target credentialling and prioritization. ScRNA-seq is also aiding the selection of relevant preclinical disease models and providing new insights into drug mechanisms of action. In clinical development, scRNA-seq can inform decision-making via improved biomarker identification for patient stratification and more precise monitoring of drug response and disease progression. Here, we illustrate how scRNA-seq methods are being applied in key steps in drug discovery and development, and discuss ongoing challenges for their implementation in the pharmaceutical industry.
pharmacology & pharmacy,biotechnology & applied microbiology
What problem does this paper attempt to address?